On October 3, Governor Gretchen Whitmer signed an executive directive focused on lowering the cost of insulin.
Under the Directive, Governor Whitmer tasked various Michigan departments and agencies with determining the feasibility of lowering costs and taking action on holding drug companies accountable. State of Michigan departments are to search for options to reduce insulin costs, which include the development of lower-cost products and the establishment of manufacturing facilities to produce insulin in Michigan.
Michigan Attorney General Dana Nessel also voiced support for better access to insulin. Previously, her department took legal action in January to enforce the Michigan Consumer Protection Act against drug companies which she claims, “has been wrongly interpreted for too long.” The act prohibits unfair and deceptive practices such as raising the pricing of certain drugs. Chief Medical Executive, Dr. Natasha Bagdasarian, commented on how reducing the cost of insulin will help improve the health of residents since high prices of insulin make access to care difficult to those who are trying to manage diabetes.
Prior to the Governor’s Executive Order, Senator Curt VanderWall (R-Ludington) introduced two different resolutions urging Governor Whitmer and different state departments to take action to make insulin more accessible and affordable. Senate Resolution 170 was adopted by the Senate on September 28. Senate Concurrent Resolution 29 was referred to the Committee on Health Policy and Human Services.
912,794 Michiganders have been diagnosed with diabetes and have more than twice the medical expenses than those who do not suffer from the disease. The directive can be found here
